Supplemental Cash Flow Information (Tables)

9 Months Ended

Sep. 30, 2022

Supplemental Cash Flow Elements [Abstract]

Summary of Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

	Nine Months Ended September 30,
	2022		2021
Supplemental cash flow information:
Interest paid	$	2,878	$	3,853
Income taxes paid		4,223		1,738
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use asset obtained in exchange for new operating lease liability		7,288		3,908
Reclassification of contingently redeemable common stock in connection with IPO		—		309,500
Issuance of common stock under partner physician group equity agreements    upon IPO		—		268,467
Offering costs accrued at end of period		—		295
Non-cash investment in unconsolidated subsidiaries		190		763

Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations

The following table summarizes cash, cash equivalents and restricted cash equivalents from continuing operations (in thousands):

	September 30, 2022		December 31, 2021
Cash and cash equivalents	$	551,287	$	1,040,039
Restricted cash and equivalents(1)		13,192		14,781
Cash, cash equivalents and restricted cash equivalents	$	564,479	$	1,054,820

(1)Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.